We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+23.66%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.11B
AUM Growth
+$195M
Cap. Flow
+$57.8M
Cap. Flow %
5.19%
Top 10 Hldgs %
48.19%
Holding
72
New
18
Increased
12
Reduced
16
Closed
18
Avg Time Held
0.6 years
Top 10 Avg Time Held
0.4 years
Top 20 Avg Time Held
0.4 years

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$49.7M
2
ENDP
Endo International plc
ENDP
+$46.9M
3
ALR
Alere Inc
ALR
+$29.1M
4
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$27.8M
5
BIIB icon
Biogen
BIIB
+$21.5M

Top Sells

Rank Stock Value
1
RAD
Rite Aid Corporation
RAD
+$45.4M
2
CELG
Celgene Corp
CELG
+$38.3M
3
GILD icon
Gilead Sciences
GILD
+$34.7M
4
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$19.4M
5
AZN icon
AstraZeneca
AZN
+$18.2M

Sector Composition

Rank Sector Weight
1 Healthcare 82.46%
2 Miscellaneous 10.8%
3 Financials 2.03%
4 Technology 1.63%
5 Communication Services 1.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ARRY icon
1
DELISTED
Array Biopharma Inc
ARRY
$96.7M 8.69%
13,125,594
+1,267,300
+11% +$9.02M
2013 Q2
7 quarters
CLVS
2
DELISTED
Clovis Oncology, Inc.
CLVS
$66.9M 6%
900,879
+179,247
+25% +$12.7M
2013 Q2
7 quarters
FOLD icon
3
DELISTED
Amicus Therapeutics
FOLD
$63.5M 5.7%
5,832,228
-1,043,046
-15% -$9.19M
2013 Q2
7 quarters
BHC icon
4
Bausch Health
BHC
$2.26B
$53.3M 4.79%
268,519
-69,958
-21% -$12.4M
2014 Q1
4 quarters
TEVA icon
5
Teva Pharmaceutical Industries Limited
TEVA
$48.3B
$53.2M 4.78%
+853,973
New +$49.7M
2015 Q1
0 quarters
ENDP
6
DELISTED
Endo International plc
ENDP
$50.3M 4.51%
+560,443
New +$46.9M
2015 Q1
0 quarters
ASPX
7
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
$41.9M 3.76%
+417,533
New +$27.8M
2015 Q1
0 quarters
BIIB icon
8
Biogen
BIIB
$35.2B
$41.3M 3.7%
97,713
+54,600
+127% +$21.5M
2014 Q4
1 quarter
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
$37.2M 3.34%
1,052,666
+68,700
+7% +$2.34M
2014 Q3
2 quarters
ALR
10
DELISTED
Alere Inc
ALR
$32.5M 2.92%
+664,138
New +$29.1M
2015 Q1
0 quarters
CMRX icon
11
DELISTED
Chimerix, Inc.
CMRX
$31.8M 2.86%
844,456
-312,728
-27% -$12.4M
2013 Q2
7 quarters
INSM icon
12
Insmed
INSM
$21.9B
$28.7M 2.58%
1,381,828
+369,457
+36% +$6.51M
2014 Q3
2 quarters
RCPT
13
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$26.3M 2.36%
159,413
-153,323
-49% -$19.4M
2013 Q3
6 quarters
LAB icon
14
Standard BioTools
LAB
$251M
$23.7M 2.13%
562,437
-48,005
-8% -$1.9M
2014 Q2
3 quarters
AET
15
DELISTED
Aetna Inc
AET
$22.6M 2.03%
+211,974
New +$20.8M
2015 Q1
0 quarters
DVA icon
16
DaVita
DVA
$11.7B
$21.6M 1.94%
+265,858
New +$20.4M
2015 Q1
0 quarters
TVTY
17
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$21.2M 1.9%
1,074,033
+5,544
+0.5% +$116K
2013 Q3
6 quarters
RARE icon
18
Ultragenyx Pharmaceutical
RARE
$1.47B
$20.7M 1.85%
+332,600
New +$18.5M
2015 Q1
0 quarters
OXFD
19
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$19.9M 1.79%
1,415,482
+344,487
+32% +$4.69M
2013 Q4
5 quarters
CIVI icon
20
DELISTED
Civitas Solutions, Inc.
CIVI
$18.4M 1.65%
879,485
– –
2014 Q3
2 quarters
CSLT
21
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$18.1M 1.63%
2,336,498
+1,089,230
+87% +$9.32M
2014 Q1
4 quarters
MODN icon
22
DELISTED
MODEL N, INC.
MODN
$17.5M 1.57%
1,461,678
– –
2013 Q4
5 quarters
JAZZ icon
23
Jazz Pharmaceuticals
JAZZ
$13.8B
$17.3M 1.55%
+100,000
New +$17.2M
2015 Q1
0 quarters
ZSPH
24
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$17.1M 1.53%
405,688
-119,014
-23% -$5.44M
2014 Q3
2 quarters
ADVM icon
25
DELISTED
Adverum Biotechnologies
ADVM
$17.1M 1.53%
42,113
-27,794
-40% -$11.7M
2014 Q3
2 quarters
1
2 3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2015 Portfolio in Review

As of Q1 2015, Redmile Group held 72 positions worth $1.11B, up 21% from $918M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Redmile Group deployed $57.8M of net new capital in Q1 2015, opening 18 new positions and adding to 12 existing holdings. Its largest new stake was Teva Pharmaceutical Industries Limited: 853,973 shares worth $53.2M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 86% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was RECEPTOS INC COM STK (DE), an estimated $19.4M trimmed.

  • Redmile Group's largest Q1 2015 buy was Teva Pharmaceutical Industries Limited: 853,973 shares worth $53.2M.
  • Redmile Group added most to Biogen in Q1 2015, an estimated $21.5M increase.
  • Redmile Group's biggest Q1 2015 reduction was RECEPTOS INC COM STK (DE), cutting an estimated $19.4M.
  • Redmile Group fully exited Rite Aid Corporation in Q1 2015, selling an estimated $45.4M.
  • Redmile Group's ten largest holdings make up 48% of its $1.11B portfolio in Q1 2015.
  • Redmile Group opened 18 new positions and closed 18 in Q1 2015.
  • Redmile Group's portfolio value rose 21% quarter-over-quarter to $1.11B.

Based on Redmile Group's 13F filing for Q1 2015, filed 18 May 2015.